Introduction

Piotr Rutkowski

Vol 20, Supp. A (2024)

Other materials agreed with the Editors

Efficacy of targeted therapies in the treatment of patients with melanoma harboring BRAF V600 mutation with central nervous system metastases

Monika Dudzisz-Śledź, Piotr Rutkowski

Vol 20, Supp. A (2024)

Review paper

Treatment with encorafenib and binimetinib of elderly female patient with BRAF-mutated melanoma with central nervous system metastases

Monika Dudzisz-Śledź

Vol 20, Supp. A (2024)

Case report

Melanoma of unknown origin with central nervous system metastases

Marta Pabianek, Magdalena Ciążyńska

Vol 20, Supp. A (2024)

Case report

Response to encorafenib and binimetinib therapy after prior treatment with targeted therapy and immunotherapy in melanoma patient with brain metastases

Łukasz Galus

Vol 20, Supp. A (2024)

Case report

Patient with M1d melanoma treated with encorafenib and binimetinib with partial response in the second line

Paulina Jagodzińska-Mucha

Vol 20, Supp. A (2024)

Case report

Treatment of advanced skin melanoma with BRAF V600 mutation with central nervous system metastases with encorafenib in combination with binimetinib

Natasza Kempa-Kamińska

Vol 20, Supp. A (2024)

Case report

Encorafenib in combination with binimetinib in second line palliative treatment in 44-year patient with symptoms of spinal cord compression

Joanna Lompart

Vol 20, Supp. A (2024)

Case report

Effectiveness of rechallenge with BRAF/ /MEK inhibitors in patient with advanced melanoma with BRAF V600 mutation

Katarzyna Woźniak

Vol 20, Supp. A (2024)

Case report

A case of a patient treated with targeted therapy in brain metastases of melanoma with BRAF V600 mutation

Jan Żurawski

Vol 20, Supp. A (2024)

Case report